Mergers & Acquisitions ·
XTL Biopharmaceuticals Ltd. consummated its acquisition of Psyga Bio Ltd. on June 30, 2026, acquiring approximately…
XTLBXtl Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd. consummated its acquisition of Psyga Bio Ltd. on June 30, 2026, acquiring approximately 83.40% of Psyga Bio's share capital through the issuance of ADSs representing up to 33.36% of XTL's issued and outstanding capital. The transaction includes milestone-based additional ADS or warrant issuance representing up to 25% of the Company's capital. Concurrently, the company completed a following private placement of US$1,500,000 at US$2.70 per ADS, which included warrants with adjustable exercise prices. XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on expanding its asset portfolio with IP-based assets.